Tarsus Pharmaceuticals, Inc. TARS
77.67 USD +1.72 (+2.26%)
Regular-session close
78.00 +0.33 +0.42%
After hours · Nov 19, 5:24 PM ET
75.61 Day range 78.08
53.89 52-week range 91.53
- YTD
- -5.14%
- 1 year
- +0.73%
News
defenseworld.net 8,971 Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Commonwealth Equity Services LLC Commonwealth Equity Services LLC reduced its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 11.2% in the third quarter, according to its most recent 13F filing with the…
benzinga.com Short Seller Flagged Nvidia China Worries Months Ago: Here’s How Much Stock Has Fallen Since A short report on Nvidia stock in May got mostly ignored. Six months later, it's getting increased attention for being right.
globenewswire.com Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.
benzinga.com HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $106 HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $106.
marketbeat.com Tarsus Pharmaceuticals Q3 Earnings Call Highlights Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye…
seekingalpha.com Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
zacks.com Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.benzinga.com UPDATE: Tarsus Pharmaceuticals Q3 Adj. EPS $(0.78) Beats $(2.73) Estimate, Sales $194.569M Beat $186.598M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(2.73) by 71.43 percent. This is a 160 percent decrease over losses…
benzinga.com Tarsus Pharmaceuticals Q3 2026 Earnings Call Transcript Tarsus Pharmaceuticals (NASDAQ:TARS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in…
zacks.com How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78% The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is…
seekingalpha.com My 'Eye' Is On Tarsus Pharmaceuticals Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both…
globenewswire.com Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3,…
globenewswire.com Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026.…
zacks.com Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
seekingalpha.com Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options Tarsus Pharmaceuticals is transitioning from a single-product launch story to a cash-generating eye care platform, with XDEMVY now funding the business. TARS raised XDEMVY 2026 net sales guidance to…
globenewswire.com Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry…
defenseworld.net Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
globenewswire.com Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no…
defenseworld.net 114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the second quarter, according to the company in its most recent disclosure with the Securities…
globenewswire.com Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group.…
globenewswire.com Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells…
globenewswire.com Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today…
marketbeat.com Tarsus Pharmaceuticals Q2 Earnings Call Highlights Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding…
